Health Canada safety review finds possible link between Fibristal and risk of liver injury

Health Canada safety review finds possible link between Fibristal and risk of liver injury. What should you do?

What you should do

Important safety information for patients:

  • Inform your healthcare provider if you currently have or have previously had liver problems, or if you have any doubts about the condition of your liver.
  • Be aware that your healthcare provider will do blood tests before, during and after treatment with Fibristal to assess your liver function.
  • Stop treatment and contact your healthcare provider immediately if you develop symptoms of liver injury (such as tiredness, yellowing of the skin, darkening of the urine, or nausea and vomiting).
  • If you are using Fibristal and have concerns, talk to your healthcare provider or pharmacist.

Important information for healthcare providers:

  • Do not prescribe Fibristal to patients who currently have or have previously had liver problems.
  • Inform your patient about the risk of a rare but serious liver injury associated with  the use of Fibristal and the need for monitoring their liver function before, during and after treatment.
  • Inform your patient about the signs and symptoms of liver injury and the need to stop Fibristal treatment and consult a physician should they occur.

 

 

close